ICD-10-CM code · FY2027
F14.15 Cocaine abuse with cocaine-induced psychotic disorder
Header codeNot billable: use one of the 3 billable codes below
About F14.15
- Code
- F14.15
- Billable
- No, header
- Short description
- Cocaine abuse with cocaine-induced psychotic disorder
- Category
- F14 Cocaine related disorders
- Block
- F10-F19 Mental and behavioral disorders due to psychoactive substance use
- Chapter
- 5 Mental, Behavioral and Neurodevelopmental disorders
- Code set
- FY2027, October 1, 2026 to September 30, 2027
EvidencePulse™by 2 Minute Medicine®
Go deeper into cocaine use.
Ask about the latest evidence, the landmark trials or what guidelines recommend, with every study cited. No ads, no sponsored answers.
Coding notes for F14.15
No notes of its own; the notes below apply from the codes above it.
Also applies, from F14.1 Cocaine abuse
Excludes1 Not coded here: never report these together with this code (use the code given instead).
Also applies, from F14 Cocaine related disorders
Excludes2 Not part of this condition, but a patient can have both: report both codes when both apply.
- other stimulant-related disorders (F15.-)
Chapter 5 notes (apply to every code in it)
Includes Conditions this code covers.
- disorders of psychological development
Codes under F14.15 3
Related codes in F14.1
- F14.10 Cocaine abuse, uncomplicatedBillable
- F14.11 Cocaine abuse, in remissionBillable
- F14.12 Cocaine abuse with intoxicationHeader
- F14.13 Cocaine abuse, unspecified with withdrawalBillable
- F14.14 Cocaine abuse with cocaine-induced mood disorderBillable
- F14.18 Cocaine abuse with other cocaine-induced disorderHeader
- F14.19 Cocaine abuse with unspecified cocaine-induced disorderBillable
Latest research on cocaine use
- Transgender veterans may be more likely to use amphetamine, cocaine, and cannabis than cisgender veterans
- Heterogenous pattern of cocaine usage in the United States
- Contingency management programs linked to decreased cocaine use among adults
- Glucagon-like peptide-1 receptor agonists show potential in reducing substance use disorders
- 2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options
2MM+
Read the research behind every diagnosis
2MM+ gives you every study summary in full, Classics downloads of the landmark trials, EvidencePulse and HypeCheck, and ad-free reading.
See 2MM+ plansICD-10-CM FY2027 code set, as published by the CDC National Center for Health Statistics (NCHS) and CMS, effective October 1, 2026 to September 30, 2027. Codes, titles and notes are shown as published. Check payer rules and the official guidelines before billing. This page is not medical advice.
Get the app